Payment overview · 2025
General Payments
$33,627.12
75 reported records · 13 companies
Healthcare provider profile · identity verified
Matthew C Bunte, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · INDEPENDENCE, MO · NPI 1518039239
Verified facts
What the public records show
CMS Open Payments records show Matthew C Bunte, MD received $33,627.12 in general payments during 2025 across 75 reported records.
Abbott Laboratories accounted for 72.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Abbott Laboratories | Unresolved — no canonical attribution shown | $24,207.96 | 72.0% | 43 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $8,640.17 | 25.7% | 12 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $147.84 | 0.4% | 1 | 2025 |
| Inari Medical, Inc. | Unresolved — no canonical attribution shown | $137.68 | 0.4% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $115.42 | 0.3% | 4 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $107.16 | 0.3% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $98.30 | 0.3% | 3 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $69.11 | 0.2% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$34.55 | 0.1% | 1 | 2025 |
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $22.97 | 0.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.11 | 0.1% | 1 | 2025 |
| Zimmer Biomet Holdings, Inc. | Unresolved — no canonical attribution shown | $14.68 | 0.0% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.17 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $12,200.00 | 3 |
| Travel and Lodging | $10,611.94 | 21 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $8,000.00 | 5 |
| Food and Beverage | $2,315.18 | 45 |
| Compensation for serving as faculty or as a speaker for a medical education program | $500.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $11,878.15 | 35 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $9,687.50 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $8,640.17 | 12 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $2,375.77 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $232.18 | 2 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $147.84 | 1 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Inari Medical, Inc. | $137.68 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Inari Medical, Inc. | $137.68 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $115.42 | 4 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $98.30 | 3 | 2025 |
Source payment records
|
|||||
| Azurion 5 M20 Normalized: azurion 5 m20 |
Device | Philips North America LLC | $75.55 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $69.11 | 4 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $34.55 | 1 | 2025 |
Source payment records
|
|||||
| PRESSUREWIRE Normalized: pressurewire |
Device | Abbott Laboratories | $34.36 | 1 | 2025 |
Source payment records
|
|||||
| Zenition 70 Normalized: zenition 70 |
Device | Philips North America LLC | $31.61 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $22.97 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.11 | 1 | 2025 |
Source payment records
|
|||||
| STERNALOCK Normalized: sternalock |
Device | Zimmer Biomet Holdings, Inc. | $14.68 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
199 | 56 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 341 | 113 |
| Atorvastatin Calcium | Atorvastatin Calcium | 325 | 106 |
| Losartan Potassium | Losartan Potassium | 277 | 98 |
| Ezetimibe | Ezetimibe | 242 | 91 |
| Carvedilol | Carvedilol | 235 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 218 | 74 |
| Jardiance | Empagliflozin | 199 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 193 | 73 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 186 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 59 |
| Spironolactone | Spironolactone | 180 | 75 |
| Eliquis | Apixaban | 179 | 53 |
| Lisinopril | Lisinopril | 131 | 45 |
| Pantoprazole Sodium | Pantoprazole Sodium | 105 | 30 |
| Xarelto | Rivaroxaban | 87 | 23 |
| Cilostazol | Cilostazol | 83 | 29 |
| Repatha Sureclick | Evolocumab | 82 | 27 |
| Furosemide | Furosemide | 81 | 30 |
| Ozempic | Semaglutide | 71 | 18 |
| Warfarin Sodium | Warfarin Sodium | 66 | 18 |
| Entresto | Sacubitril/Valsartan | 50 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 35 | 15 |
| Praluent Pen | Alirocumab | 34 | suppressed |
| Chlorthalidone | Chlorthalidone | 33 | 11 |
| Potassium Chloride | Potassium Chloride | 28 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | 12 |
| Torsemide | Torsemide | 27 | 13 |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Nitroglycerin | Nitroglycerin | 21 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 21 | suppressed |
| Metformin Hcl | Metformin Hcl | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Ranolazine Er | Ranolazine | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 14 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Repatha Syringe | Evolocumab | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Simvastatin | Simvastatin | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33,627.12 · 75 records | Abbott Laboratories | Azurion 5 M20, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK PERIPHERAL, ESPRIT, FLOWTRIEVER CATHETER, S, Indigo System, LEQVIO, LifeVest, MICRA, PERCLOSE PROSTYLE, PRESSUREWIRE, REPATHA, STERNALOCK, SUPERA, SYMPHONY CATHETER, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, VOQUEZNA, ZEPBOUND, Zenition 70 | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error